Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
09 August, 2020 02:31 IST
USFDA revokes Aurobindo Pharma's VAI status for Hyderabad unit
Source: IRIS | 21 Feb, 2020, 07.33PM
Comments  |  Post Comment

Aurobindo Pharma said that the US Food and Drug Administration (USFDA) inspection at its Unit IV is still open and under review.

The drug regulator has also revoked the Voluntary Action Initiated (VAI) status given to the facility, it said.

''The Company received a communication that the inspection conducted by the US Food and Drug Administration (USFDA) at our aforesaid Unit IV, from November 4, 2019, to November 13, 2019, is still open and under review, by way of rescindment of 90-day VAI letter that was issued by them on February 18, 2020,'' Aurobindo Pharma said in a regulatory filing on Friday.

On Wednesday, the drug major informed the receipt of the Establishment Inspection Report with Voluntary Action Initiated (VAI) status from the US drug regulator. The USFDA issued the report after concluding an inspection at the drug manufacturer's key injectable plant Unit 4 in Hyderabad.

Shares of the company declined Rs 2.65, or 0.44%, to settle at Rs 596.90. The total volume of shares traded was 274,370 at the BSE (Thursday).

Aurobindo Pharma Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer